Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know

Bone Marrow Transplantation volume 33, pages 137–152 (2004)Cite this article

Summary:

Pharmacokinetic drug interactions among hematopoietic stem cell transplant recipients can result in either increases in serum concentrations of medications, which may lead to enhanced toxicity; or reduced serum concentrations, which can lead to treatment failure and the emergence of post transplant complications. The use of drugs that have a narrow therapeutic index, such as cyclosporine/tacrolimus (calcineurin inhibitors), increases the significance of these interactions when they occur. This report will review the clinical data evaluating the drug interactions of relevance to HSCT clinical practice, focusing on the pharmacokinetic interactions, and provides recommendations for managing these interactions to avoid both toxicity and treatment failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Venkatakrishnan K, von Moltke LL, Greenblatt DJ . Effects of the antifungal agents on oxidative drug metabolism clinical relevance. Clin Pharmacokinet 2000; 38: 111–180.

    CAS  PubMed  Google Scholar 

  2. Flockhart DA . Cytochrome P450 drug interaction table (online). Available from URL: http://medicine.iupui.edu/flockhart/ (accessed October 22, 2002).

  3. Watkins PB . Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990; 10: 235–250.

    CAS  PubMed  Google Scholar 

  4. Pea F, Farlanut M . Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833–868.

    CAS  PubMed  Google Scholar 

  5. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157–163.

    CAS  PubMed  Google Scholar 

  6. Przepiorka D, Nash RA, Wingard JR et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 94–97.

    CAS  PubMed  Google Scholar 

  7. Lampen A, Christians V, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315–1324.

    CAS  PubMed  Google Scholar 

  8. Christians U, Jacobsen W, Benet LZ et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813–851.

    CAS  PubMed  Google Scholar 

  9. Osowski CL, Dix SP, Lin L et al. Evaluation of the drug interaction between high dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268–1272.

    CAS  PubMed  Google Scholar 

  10. Manez R, Martin M, Raman D et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521–1523.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Leather HL, Wingard JR . Characterizing the pharmacokinetic (PK) drug interaction between intravenous (IV) itraconazole (ITRA) and IV tacrolimus (FK506) or IV cyclosporine (CyA) in allogeneic bone marrow transplant (alloBMT) patients. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16–19 December 2001 (abstract A-33). Washington, DC: American Society of Microbiology, 2001.

    Google Scholar 

  12. Banerjee R, Leaver N, Lyster H et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 2001; 33: 1600–1602.

    CAS  PubMed  Google Scholar 

  13. Billaud EM, Guillemain R, Tacco F et al. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271–272.

    CAS  PubMed  Google Scholar 

  14. Capone D, Gentile A, Imperatore P et al. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999; 33: 1124–1125.

    CAS  PubMed  Google Scholar 

  15. Furlan V, Parquin F, Penaud JF et al. Interaction between tacrolimus and itraconazole in a heart–lung transplant recipient. Transplant Proc 1998; 30: 187–188.

    CAS  PubMed  Google Scholar 

  16. Outeda Macias M, Salvador P, Hurtado JL et al. Tacrolimus–itraconazole interaction in a kidney transplant patient. Ann Pharmacother 2000; 34: 536.

    CAS  PubMed  Google Scholar 

  17. Wood N, Tan K, Allan R et al. Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16–19 December 2001 (abstract A-20). American Society of Microbiology: Washington, DC, 2001.

    Google Scholar 

  18. Jones TE, Morris RG . Pharmacokinetic interaction between tacrolimus and diltiazem: dose–response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381–388.

    CAS  PubMed  Google Scholar 

  19. Hebert MF, Lam AY . Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680–682.

    CAS  PubMed  Google Scholar 

  20. Schulman SL, Shaw LM, Jabs K et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 1998; 65: 1397–1398.

    CAS  PubMed  Google Scholar 

  21. Sheth SR, Hicks K, Ippoliti C et al. Safety, tolerability and drug interactions of adjuvant imatinib mesylate (Gleevec) within the first 100 days following stem cell transplantation (SCT) in patients with Ph+CML and Ph+ALL at high risk for recurrence. Blood 2002; 100: 635a (abstract 2500).

    Google Scholar 

  22. Gomez G, Alvarez ML, Errasti P et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Transplant Proc 1999; 31: 2250–2251.

    CAS  PubMed  Google Scholar 

  23. Wolter K, Wagner K, Philipp T et al. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207–208.

    CAS  PubMed  Google Scholar 

  24. Jensen C, Jordan M, Shapiro R et al. Interaction between tacrolimus and erythromycin. Lancet 1994; 344: 825.

    CAS  PubMed  Google Scholar 

  25. Shaeffer MS, Collier D, Sorrell MF . Interaction between FK506 and erythromycin. Ann Pharmacother 1994; 28: 280–281.

    CAS  PubMed  Google Scholar 

  26. Padhi ID, Long P, Basha M et al. Interaction between tacrolimus and erythromycin. Ther Drug Monitor 1997; 19: 120–122.

    CAS  Google Scholar 

  27. McLaughlin GE, Rossique-Gonzalez M, Gelman B et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant Proc 2000; 32: 665–668.

    CAS  PubMed  Google Scholar 

  28. Thompson PA, Mosley CA . Tacrolimus–phenytoin interaction. Ann Pharmacother 1996; 30: 544.

    CAS  PubMed  Google Scholar 

  29. Hebert MF, Fisher RM, March CL et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91–96.

    CAS  PubMed  Google Scholar 

  30. Chenhsu RY, Loong CC, Chou MH et al. Renal allograft dysfunction associated with rifampin–tacrolimus interaction. Ann Pharmacother 2000; 34: 27–31.

    CAS  PubMed  Google Scholar 

  31. Furlan V, Perello L, Jacquemin E et al. Interaction between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995; 59: 1217–1218.

    CAS  PubMed  Google Scholar 

  32. Bolley R, Zulke C, Kammerl M et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002; 73: 1009–1010.

    PubMed  Google Scholar 

  33. Boubenider S, Vincent I, Lambotte O et al. Interaction between theophylline and tacrolimus in a renal transplant patient. Nephrol Dial Transplant 2000; 15: 1066–1068.

    CAS  PubMed  Google Scholar 

  34. Collignon P, Hurley B, Mitchell D . Interaction of fluconazole with cyclosporin. Lancet 1989; 1: 1262.

    CAS  PubMed  Google Scholar 

  35. Tett S, Carey D, Lee HS . Drug interactions with fluconazole. Med J Austr 1992; 156: 365.

    CAS  Google Scholar 

  36. Sugar AM, Saunders C, Idelson BA et al. Interaction of fluconazole and cyclosporine. Ann Intern Med 1989; 110: 844.

    CAS  PubMed  Google Scholar 

  37. Graves NM, Matas AJ, Hilligoss DM et al. Fluconazole/cyclosporine interaction. Clin Pharmacol Ther 1990; 47: 208.

    Google Scholar 

  38. Ehninger G, Jaschonek K, Schuler U et al. Interaction of fluconazole with cyclosporin. Lancet 1989; 2: 104–105.

    CAS  PubMed  Google Scholar 

  39. Lucey MR, Kolars JC, Merion RM et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990; 335: 11–15.

    CAS  PubMed  Google Scholar 

  40. Lopez-Gill JA . Fluconazole–cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993; 27: 427–430.

    Google Scholar 

  41. Canafax DM, Graves NM, Hilligoss DM et al. Interaction between cyclosporin and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014–1018.

    CAS  PubMed  Google Scholar 

  42. Kruger HU, Schuler U, Zimmermann R et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989; 24: 781–786.

    CAS  PubMed  Google Scholar 

  43. Kramer MR, Marshall SE, Denning DW et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327–329.

    CAS  PubMed  Google Scholar 

  44. Kwan JT, Foxall PJ, Davidson DG et al. Interaction of cyclosporin and itraconazole. Lancet 1987; 2: 282.

    CAS  PubMed  Google Scholar 

  45. Romero AJ, Pogamp PL, Nilsson LG, Wood N . Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226–234.

    CAS  PubMed  Google Scholar 

  46. McCauley J, Ptachcinski RJ, Shapiro R . The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955–3957.

    CAS  PubMed  Google Scholar 

  47. Lele P, Peteson P, Yang S et al. Cyclosporine and tegretol – another drug interaction. Kidney Int 1985; 27: 34.

    Google Scholar 

  48. Steinfort CL, McConachy KA . Cyclosporin–chloramphenicol drug interaction in a heart–lung transplant recipient. Med J Austr 1994; 161: 455.

    CAS  Google Scholar 

  49. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635–1642.

    CAS  PubMed  Google Scholar 

  50. McLellan RA, Drobitch RK, McLellan H et al. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995; 58: 322–327.

    CAS  PubMed  Google Scholar 

  51. Hoey LL, Lake KD . Does ciprofloxacin interact with cyclosporine? Ann Pharmacother 1994; 28: 93–96.

    CAS  PubMed  Google Scholar 

  52. Doose DR, Walker SA, Chien SC et al. Levofloxacin does not alter cyclosporine disposition. J Clin Pharmacol 1998; 38: 90–93.

    CAS  PubMed  Google Scholar 

  53. Sadaba B, Lopez de Ocariz A, Azanza JR et al. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42: 393–395.

    CAS  PubMed  Google Scholar 

  54. Spicer ST, Liddle C, Chapman JR et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997; 43: 194–196.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Harnett JD, Parfrey PS, Paul MD et al. Erythromycin–cyclosporine interaction in renal transplant recipients. Transplantation 1987; 43: 316–318.

    CAS  PubMed  Google Scholar 

  56. Shipkova M, Armstrong VW, Kuypers D et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monitor 2001; 23: 717–721.

    CAS  Google Scholar 

  57. Schmidt H, Naumann R, Laschonek K et al. Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 212–213.

    CAS  PubMed  Google Scholar 

  58. Keown PA, Laupacis A, Carruthers G et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984; 38: 304–306.

    CAS  PubMed  Google Scholar 

  59. Freeman DL, Laupacis A, Keown PA et al. Evaluation of cyclosporine–phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol 1984; 18: 887–893.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Stamatakis MK, Richards JG . Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother 1997; 31: 576–578.

    CAS  PubMed  Google Scholar 

  61. Hebert MF, Roberts JP, Prueksaritanont T et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453–457.

    CAS  PubMed  Google Scholar 

  62. Offerman G, Keller F, Molzahn M . Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385–387.

    Google Scholar 

  63. Modry DL, Stinson EB, Oyer PE et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313–314.

    CAS  PubMed  Google Scholar 

  64. Data on file. Wyeth Pharmaceuticals: Madison, NJ.

  65. Christ B, Brockmeier D, Hauck EW et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. Urology 2001; 58: 589–593.

    CAS  PubMed  Google Scholar 

  66. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548–549.

    CAS  PubMed  Google Scholar 

  67. Breidenbach TH, Kliem V, Burg M et al. Profound drop of cyclosporin A whole blood trough levels caused by St John's wort (Hypericum perforatum). Transplantation 2000; 69: 2229–2230.

    CAS  PubMed  Google Scholar 

  68. Barone GW, Gurley BJ, Ketel BL et al. Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013–1016.

    CAS  PubMed  Google Scholar 

  69. Breidenbach T, Hoffmann MW, Becker T et al. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912.

    CAS  PubMed  Google Scholar 

  70. Karliova M, Treichel V, Malago M et al. Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853–855.

    CAS  PubMed  Google Scholar 

  71. Mai I, Kruger H, Budde K et al. Hazardous pharmacokinetic interaction of St John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500–502.

    CAS  PubMed  Google Scholar 

  72. Mandelbaum A, Pertzborn F, Martin-Facklam M et al. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15: 1473.

    CAS  PubMed  Google Scholar 

  73. McAlister VC, Mahalati K, Peltekian KM et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346–350.

    CAS  PubMed  Google Scholar 

  74. Slaughter RL, Edwards DJ . Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619–624.

    CAS  PubMed  Google Scholar 

  75. Nicolau DP, Crowe HM, Nightingale CH et al. Rifampin–fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29: 994–996.

    CAS  PubMed  Google Scholar 

  76. Blum RA, Wilton JH, Hilligoss DM et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420–425.

    CAS  PubMed  Google Scholar 

  77. Cadle RM, Zenon GJ, Rodriguez-Barradas MC et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 191–195.

    CAS  PubMed  Google Scholar 

  78. Mitchell AS, Holland JT . Fluconazole and phenytoin: a predictable interaction. Br Med J 1989; 298: 1315.

    CAS  Google Scholar 

  79. Howitt KM, Oziemski MA . Phenytoin toxicity induced by fluconazole. Med J Austr 1989; 151: 603–604.

    CAS  Google Scholar 

  80. Crussell-Porter LL, Rindone JP, Ford MA et al. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993; 153: 102–104.

    CAS  PubMed  Google Scholar 

  81. Black DJ, Kunze KL, Wienkers LC et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422–428.

    CAS  PubMed  Google Scholar 

  82. Baciewicz AM, Menke JJ, Bokar JA et al. Fluconazole–warfarin interaction. Ann Pharmacother 1994; 28: 1111.

    CAS  PubMed  Google Scholar 

  83. Gericke KR . Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993; 13: 508–509.

    CAS  PubMed  Google Scholar 

  84. Yeh J, Soo SC, Summerton C et al. Potentiation of action of warfarin by itraconazole. Br Med J 1990; 301: 669.

    CAS  Google Scholar 

  85. Crane JK, Shih HT . Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445–446.

    CAS  PubMed  Google Scholar 

  86. Pohjola-Sintonen S, Viitasalo M, Toivonene L et al. Torsades de pointes after terfenadine–itraconazole interaction. Br Med J 1993; 306: 186.

    CAS  Google Scholar 

  87. Kamaluddin M, McNally P, Breatnach F et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001; 90: 1204–1207.

    CAS  PubMed  Google Scholar 

  88. Jeng MR, Feusner J . Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18: 137–142.

    CAS  PubMed  Google Scholar 

  89. Sathiapalan RK, El-Solh H . Enhanced vincristine neurotoxicity from drug interactions: case report and review of the literature. Pediatr Hematol Oncol 2001; 18: 543–546.

    CAS  PubMed  Google Scholar 

  90. Bohme A, Ganser A, Hoelzer D . Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71: 311–312.

    CAS  PubMed  Google Scholar 

  91. Murphy JA, Ross LM, Gibson BE . Vincristine toxicity in five children with acute lymphoblastic leukaemia. Lancet 1995; 346: 443.

    CAS  PubMed  Google Scholar 

  92. Olkkola KT, Backman JT, Neuvonen PJ . Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481–485.

    CAS  PubMed  Google Scholar 

  93. Varhe A, Olkkola KT, Neuvonen PJ . Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601–607.

    CAS  PubMed  Google Scholar 

  94. Jalalava KM, Olkkola KT, Neuvonen PJ . Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410–415.

    Google Scholar 

  95. Tucker RM, Denning DW, Hanson LH et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165–174.

    CAS  PubMed  Google Scholar 

  96. Bonay M, Jonville-Bera AP, Diot P et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993; 9: 309–311.

    CAS  PubMed  Google Scholar 

  97. Alderman CP, Allcroft PD . Digoxin–itraconazole interaction: possible mechanisms. Ann Pharmacother 1997; 31: 438–440.

    CAS  PubMed  Google Scholar 

  98. Sachs MK, Blanchard LM, Green PJ . Interaction of itraconazole and digoxin. Clin Infect Dis 1993; 16: 400–403.

    CAS  PubMed  Google Scholar 

  99. Rex J . Itraconazole–digoxin interaction. Ann Intern Med 1992; 116: 525.

    CAS  PubMed  Google Scholar 

  100. Kauffman CA, Bagnasco FA . Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992; 15: 886–887.

    CAS  PubMed  Google Scholar 

  101. Neuvonen PJ, Jalava KM . Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61.

    CAS  PubMed  Google Scholar 

  102. Kantola T, Kivisto KT, Neuvonen PJ . Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58–65.

    CAS  PubMed  Google Scholar 

  103. Neuvonen PJ, Kantola T, Kivisto KJ . Simvastatin but not pravastatin is very susceptible to interactions with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–341.

    CAS  PubMed  Google Scholar 

  104. Vlahakos DV, Manginas A, Chilidou D et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002; 73: 1962–1964.

    CAS  PubMed  Google Scholar 

  105. Ducharme MP, Slaughter RL, Warnasse LH et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58: 617–624.

    CAS  PubMed  Google Scholar 

  106. Jaruratanasirikul S, Sriwiriyajan S . Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998; 54: 155–158.

    CAS  PubMed  Google Scholar 

  107. Drayton J, Dickinson G, Rinaldi MG . Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18: 266–267.

    CAS  PubMed  Google Scholar 

  108. Smith JA, Hardin TC, Patterson TF et al. Rifabutin decreases itraconazole plasma levels in patients with HIV-infection (abstract). Second National Conference on Human Retroviruses and Related Infections, Washington DC, January 1995.

  109. Glasmacher A, Hahn C, Molitor E et al. Definition of an itraconazole target concentration for antifungal prophylaxis. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 700). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  110. Yule SM, Walker D, Cole M et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 1999; 27: 417–421.

    CAS  PubMed  Google Scholar 

  111. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083–2088.

    CAS  PubMed  Google Scholar 

  112. Data on file. Pfizer Inc.: New York, NY.

  113. Ghahramani P, Purkins L, Kleinermans D et al. The pharmacokinetics of voriconazole and its effect on prednisolone disposition. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario 17–20 September 2000 (abstract 842). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  114. Ghahramani P, Purkins L, Kleinermans D et al. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 844). American Society of Microbiology: Washington DC, 2000.

    Google Scholar 

  115. Ghahramani P, Purkins L, Kleinermans D et al. Voriconazole potentiates warfarin-induced prolongation of prothrombin time. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 846). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  116. Ghahramani P, Purkins L, Kleinermans DJ et al. Effect of omeprazole on the pharmacokinetics of voriconazole. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 843). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  117. Wood N, Tan K, Allan R et al. Effect of voriconazole on the pharmacokinetics of omeprazole. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16–19 December 2001 (abstract A-19). American Society of Microbiology: Washington, DC, 2001.

    Google Scholar 

  118. Ghahramani P, Purkins L, Love ER et al. Drug interactions between voriconazole and phenytoin. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 847). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  119. Kehrer DF, Mathijssen RH, Verweij J et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20: 3122–3129.

    CAS  PubMed  Google Scholar 

  120. Stone JA, McCrea JB, Wickersham PJ et al. A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17–20 September 2000 (abstract 854). American Society of Microbiology: Washington, DC, 2000.

    Google Scholar 

  121. Data on file. Merck and Co.: Whitehouse Station, NJ.

  122. Stone J, Holland S, Wickersham P et al. Drug interactions between caspofungin and tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16–19 December 2001 (abstract A-13). American Society of Microbiology: Washington, DC, 2001.

    Google Scholar 

  123. Van Burik J, Ratanatharathorn V, Lipton J et al. Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG Protocol 46. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 27–30 September 2002 (abstract M-1238). Washington, DC: American Society of Microbiology, 2002.

    Google Scholar 

  124. Schmidt LE, Dalhoff K . Food–drug interactions. Drugs 2002; 62: 1481–1502.

    CAS  PubMed  Google Scholar 

  125. Becquemont L, Verstuyft C, Kerb R et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311–316.

    CAS  PubMed  Google Scholar 

  126. Kane GC, Lipsky JJ . Drug–grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933–942.

    CAS  PubMed  Google Scholar 

  127. Honig PK, Wortham DC, Lazarev A et al. Pharmacokinetics and cardiac effects of terfenadine in poor metabolizers receiving concomitant grapefruit juice. Clin Pharmacol Ther 1995; 57: 185.

    Google Scholar 

  128. Rau SE, Bend JF, Tran LT et al. Inhibition of terfenadine metabolism by co-administration of grapefruit juice in humans. Clin Invest Med 1995; 18: 95.

    Google Scholar 

  129. Kupferschmidt HH, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–28.

    CAS  PubMed  Google Scholar 

  130. Hukkinen SK, Varhe A, Olkkola KT et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127–131.

    CAS  PubMed  Google Scholar 

  131. Vincent J, Harris SI, Foulds G et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol 2000; 50: 455–463.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Josefsson M, Ahlner J . Amlodipine and grapefruit juice. Br J Clin Pharmacol 2002; 53: 405.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Ducharme MP, Warbasse LH, Edwards DJ . Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485–491.

    CAS  PubMed  Google Scholar 

  134. Yee GC, Stanley DL, Pessa JL et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955–956.

    CAS  PubMed  Google Scholar 

  135. Min DI, Ku YM, Perry PJ et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996; 62: 123–125.

    CAS  PubMed  Google Scholar 

  136. Brunner LJ, Munar MY, Vallian J et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18: 23–29.

    CAS  PubMed  Google Scholar 

  137. Emilia G, Longo G, Bertesi M et al. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood 1998; 91: 362–363.

    CAS  PubMed  Google Scholar 

  138. Ioannides-Demnos LL, Christophidis N, Ryan P et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol 1997; 24: 49–54.

    Google Scholar 

  139. McCauley J, Ptachcinski RJ, Shapiro R . The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955–3957.

    CAS  PubMed  Google Scholar 

  140. Patton PR, Brunson ME, Pfaff WW et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine sparing effect and impact on transplant outcomes. Transplantation 1994; 57: 889–892.

    CAS  PubMed  Google Scholar 

  141. Martin JE, Daoud AJ, Schroeder TJ et al. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317–337.

    CAS  PubMed  Google Scholar 

  142. Crone CC, Wise TN . Survey of alternative medicine use among organ transplant patients. J Transplant Coord 1997; 7: 123–130.

    CAS  Google Scholar 

  143. Eisenberg DM, Davis RB, Ettner SL . Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569–1575.

    CAS  PubMed  Google Scholar 

  144. Linde K, Ramirez G, Mulrow CD et al. St John's wort for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 1996; 313: 253–258.

    CAS  Google Scholar 

  145. Mathijssen RH, Verweij J, de Bruijn P et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247–1249.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Florida, Gainesville, USA

    H L Leather

Authors
  1. H L Leather
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H L Leather.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leather, H. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 33, 137–152 (2004). https://doi.org/10.1038/sj.bmt.1704316

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704316

Keywords

This article is cited by

Search

Advanced search

Quick links